ALX Oncology Holdings Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. YES☒NO☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files). YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES☐NO☒ As of May 1, 2026, the registrant had 134,562,917 shares of common stock outstanding, $0.001 par value per share. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other thanstatements of historical facts contained in this report, including statements regarding our future results of operationsand financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results ofclinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well asplans and objectives of management for future operations, are forward-looking statements. These statements involveknown and unknown risks, uncertainties and other important factors that are in some cases beyond our control andmay cause our actual results, performance or achievements to be materially different from any future results,performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,”“would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,”“potential,” or “continue” or the negative of these terms or other similar expressions. Forward-looking statementscontained in this Quarterly Report include, but are not limited to, statements about: ▪our financial performance;▪the sufficiency of our existing cash to fund our future operating expenses and capital expenditurerequirements;▪the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs foradditional financing;▪our plans relating to commercializing our product candidates, if approved, including the geographicareas of focus and our ability to grow a sales team;▪the implementation of our strategic plans for our business and product candidates;▪our ability to obtain and maintain regulatory approval of our product candidates and the timing orlikelihood of regulatory filings and approvals, including our expectation to seek special designations,such as orphan drug designation, for our product candidates for various diseases;▪our reliance on third parties to conduct preclinical research activities, and for the manufacture of ourproduct candidates;▪the beneficial characteristics, mechanisms of action, safety profile, efficacy and therapeutic effects ofour product candidates;▪the progress and focus of our current and future clinical trials, and the reporting of data from thosetrials;▪our ability to advance product candidates into and successfully complete clinical trials;▪the ability of our clinical trials, including collaborations and investigator sponsored trials, todemonstrate the safety and efficacy of our product candidates, and other positive results;▪the success of competing therapies that are or may become available;▪developments relating to our competitors and our industry, including competing product candidatesand therapies;▪our plans relating to the further development and manufacturing of our product candidates, includingadditional indications that we may pursue;▪existing regulations and regulatory developments in the United States and other jurisdictions;▪our potential and ability to successfully manufacture and supply our product candidates for clinicaltrials and for commercial use, if approved;▪our continued reli